Loading
A phase 3 trial of Sacituzumab tirumotecan, FOLFIRI, Paclitaxel / nab-paclitaxel in oesophageal cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) is a phase 3 interventional study registered as NCT06356311 by Merck Sharp & Dohme LLC, with 450 participants planned, started 2024-05-03 and due to reach its primary completion in 2027-01-04. Interventions recorded: Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan, Paclitaxel, Docetaxel. Conditions listed: Gastroesophageal Cancer. No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Paclitaxel / nab-paclitaxel.
Shares Sacituzumab tirumotecan, Docetaxel, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, Docetaxel, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, Docetaxel, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Oesophageal and junctional adenocarcinoma, Sacituzumab tirumotecan, Merck & Co. (MSD), Oesophageal cancer.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Paclitaxel / nab-paclitaxel.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).